Efficacy Results In ECLIPSE, Moderate-To-Severe Psoriasis

Endpoint

J&J's Tremfya

Novartis' Cosentyx

P-value

Primary endpoint

PASI 90 at 48 weeks

84.5%

70%

p<>

First major secondary endpoint

PASI 75 at weeks 12 and 48

84.6%

80.2%

P<0.001 for="" noninferiority;="" p="0.062" for="">

Other secondary endpoints, p-values considered nominal, as superiority not shown on first secondary endpoint

PASI 100 at week 48

58.2%

48.4%

Nominal p<>

Investigator's Global Assessment (IGA) Score of 0 (cleared) at week 48

62.2%

50.4%

Nominal p<>

IGA score 0 or 1 (cleared or minimal disease) at week 48

85%

74.9%

Nominal p<>

PASI 75 at week 12

89.3%

91.6%

p<0.001 for="">

PASI 90 at week 12

69.1%

76.1%

p=0.127 for non-inferiority

ECLIPSE: J&J's Tremfya Beats Novartis' Cosentyx For Long-Term Psoriasis Clearance

More from Clinical Trials